Travere Therapeutics, Inc.
Moat Score — Travere Therapeutics, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | FILSPARI's full FDA approval as the first non-immunosuppressive oral IgAN therapy is a real regulatory and clinical-data moat, though the company itself discloses that certain commercial products lack full patent protection and FILSPARI's European patent faces active opposition. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Travere pays away 15%-17% of sparsentan net sales to Ligand and BMS and a Thiola royalty to Mission, so its cost structure is burdened by third-party royalty obligations rather than reflecting a low-cost position. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the first fully approved oral therapy for a progressive, under-treated rare kidney disease, FILSPARI commands specialty-drug pricing, though a wave of new IgAN entrants from Novartis, Otsuka, and Vera will test that pricing power over time. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in specialty pharmaceutical sales; value comes from clinical data and physician relationships, not from a platform that grows more valuable as more users join. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Nephrologists who have titrated a patient onto FILSPARI and are seeing slowed kidney function decline have some incentive not to switch, but new IgAN entrants with differentiated mechanisms could still displace it in treatment-naive patients. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | IgA nephropathy is a large enough rare-disease market to support multiple specialty entrants, so Travere's position, while strong today, is not protected by a market too small for the half-dozen large competitors now entering. |